On Dec. 13, CHI NHSA, CHI HRSS released drug list for insurance.
CHI NHSA and CHI HRSS jointly issued a notice regarding the National basic medical insurance, work injury insurance, and maternity insurance drug list (2023).
The notice emphasizes the need for timely adjustments to payment coverage, standardization of payment criteria, and promoting of the use of listed drugs.
Notice
Emphasizes importance of adhering to 2023 drug list for medical insurance purposes, prohibits independent adjustments to listed drugs, categories by provinces, regions.
Information systems, databases shall be updated to include new drugs within payment coverage, payment standards shall be standardized for competitively priced drugs.
Excess costs above the payment standard are to be borne by insured individuals.
Encourages the prioritization of competitively-priced drugs to reduce patient costs.
Provinces shall list negotiated drugs on provincial procurement platform by Dec. 2023.
They shall improve dual-channel system, explore models for drugs for rare diseases.
Effectiveness
The 2023 drug list will be implemented from Jan. 1, 2024, replacing the 2022 list.
Nov. 2024 Drug List 2024
On Nov. 28, 2024, CHI NHSA, CHI HRSS issued notice on the National basic medical insurance, work injury insurance, and maternity insurance drug list (2024).
The 2024 drug list will replace the 2023 drug list above, effective from Jan. 1, 2025.
A six-month transition period will be given to drugs that have not been renewed, and the medical insurance fund can continue to pay for them before Jun. 30, 2025.
Medical insurance bureaus should actively develop commercial health insurance and support firms in designing products or updating scope of compensation per 2024 list.
Encourage local governments to explore the development of commercial health insurance in hospitals to achieve one-stop settlement with basic medical insurance.
